NASA’s new dark energy space telescope can also detect killer asteroids
technologyreview.com·1h ago
AI Research
arXiv CS.AI·May 26·5 min read
A Large-Scale Dataset and Benchmark: Do Protein-Ligand Models Learn Binding Sites or Just Binding Likelihood?
TL;DR
Existing protein-ligand models often fail to determine specific binding sites, focusing instead on binding likelihood. InteractBind, a new dataset of around 100,000 protein-ligand pairs, was created to evaluate binding-site localization and non-covalent interactions.
✦ Why It Matters
Engineers and researchers can leverage InteractBind to improve model interpretability in protein-ligand interactions.
Key Takeaways
- Utilize InteractBind for evaluating protein-ligand models.
- Focus on improving binding-site localization in model development.
- Explore the variability in non-covalent interaction types.
- Aim for more interpretable models in drug discovery applications.
Full Summary
Protein-ligand interactions are crucial for drug discovery, yet current benchmarks primarily assess whether proteins and ligands bind and the strength of that binding. To fill this gap, InteractBind was developed, featuring approximately 100,000 protein-ligand pairs and a benchmark focused on binding-site localization.
This benchmark evaluates models based on interaction maps that detail six types of non-covalent interactions, which are essential for understanding molecular recognition. Eight existing models were tested using InteractBind, revealing that they performed well in binary binding predictions but poorly in localizing binding sites.
The findings indicated significant variability in performance across different types of non-covalent interactions. InteractBind sets a new standard for evaluating protein-ligand models, encouraging the development of more interpretable and physically grounded approaches.